Cargando…

Cost-Effectiveness of Once-Daily Single-Inhaler COPD Triple Therapy in Spain: IMPACT Trial

PURPOSE: Given between-country differences in healthcare systems, treatment costs, and disease management guidelines, country-specific cost-effectiveness analyses are important. This study evaluated the cost-effectiveness of once-daily fluticasone furoate/umeclidinium/vilanterol (FF/UMEC/VI) versus...

Descripción completa

Detalles Bibliográficos
Autores principales:	Paly, Victoria Federico, Vallejo-Aparicio, Laura Amanda, Martin, Alan, Izquierdo, José Luis, Riesco, Juan Antonio, Soler-Cataluña, Juan José, Abreu, Catarina, Biswas, Chandroday, Ismaila, Afisi S
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Dove 2022
Materias:	Original Research
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9766529/ https://www.ncbi.nlm.nih.gov/pubmed/36561129 http://dx.doi.org/10.2147/COPD.S366765

Ejemplares similares

Cost-Effectiveness Analysis of a Once-Daily Single-Inhaler Triple Therapy for Patients with Chronic Obstructive Pulmonary Disease (COPD) Using the FULFIL Trial: A Spanish Perspective
por: Schroeder, Melanie, et al.
Publicado: (2020)

Cost-Effectiveness Of Once-Daily Single-Inhaler Triple Therapy In COPD: The IMPACT Trial
por: Ismaila, Afisi S, et al.
Publicado: (2019)

Impact of COPD Exacerbations and Burden of Disease in Spain: AVOIDEX Study
por: Soler-Cataluña, Juan José, et al.
Publicado: (2023)

Clinical effectiveness of once-daily fluticasone furoate/umeclidinium/vilanterol in usual practice: the COPD INTREPID study design
por: Worsley, Sally, et al.
Publicado: (2019)

Once-Daily Triple Therapy in Patients with Advanced COPD: Healthcare Resource Utilization Data and Associated Costs from the FULFIL Trial
por: Ismaila, Afisi S., et al.
Publicado: (2017)

Impact of Single Combination Inhaler versus Multiple Inhalers to Deliver the Same Medications for Patients with Asthma or COPD: A Systematic Literature Review
por: Zhang, Shiyuan, et al.
Publicado: (2020)

Clinical and Economic Impact of Long-Term Inhaled Corticosteroid Withdrawal in Patients with Chronic Obstructive Pulmonary Disease Treated with Triple Therapy in Spain
por: Neches García, Victoria, et al.
Publicado: (2022)

Inhaled Corticosteroid Use Among COPD Patients in Primary Care in Spain
por: Miravitlles, Marc, et al.
Publicado: (2022)

Cost-effectiveness analysis of a single-inhaler triple therapy for COPD in the UK
por: Fenwick, Elisabeth, et al.
Publicado: (2021)

Clinical audit of COPD in outpatient respiratory clinics in Spain: the EPOCONSUL study
por: Calle Rubio, Myriam, et al.
Publicado: (2017)

COPD Exacerbation Syndrome: The Spanish Perspective on an Old Dilemma
por: Soler-Cataluña, Juan Jose, et al.
Publicado: (2022)

Is single-inhaler triple therapy for COPD cost-effective in the UK? The IMPACT trial
por: Martin, Alan, et al.
Publicado: (2022)

Characteristics of New Users of Single- and Multiple-Inhaler Triple Therapy for COPD in Primary Care in England
por: Rothnie, Kieran J, et al.
Publicado: (2022)

Preventing clinically important deterioration with single-inhaler triple therapy in COPD
por: Naya, Ian, et al.
Publicado: (2018)

The concept of control of COPD in clinical practice
por: Soler-Cataluña, Juan José, et al.
Publicado: (2014)

A new approach to grading and treating COPD based on clinical phenotypes: summary of the Spanish COPD guidelines (GesEPOC)
por: Miravitlles, Marc, et al.
Publicado: (2013)

Cost-Effectiveness of Single-Inhaler Triple Therapy (FF/UMEC/VI) versus Tiotropium Monotherapy in Patients with Symptomatic Moderate-to-Very Severe COPD in the UK
por: Kendall, Robyn, et al.
Publicado: (2023)

INTREPID: single- versus multiple-inhaler triple therapy for COPD in usual clinical practice
por: Halpin, David M.G., et al.
Publicado: (2021)

Single-Inhaler Triple Therapy in Patients with Advanced COPD: Bayesian Modeling of the Healthcare Resource Utilization Data and Associated Costs from the IMPACT Trial
por: Gabrio, Andrea, et al.
Publicado: (2022)

Is once enough? Understanding the preferences of COPD and asthma patients for once- versus twice-daily treatment
por: Horne, Rob
Publicado: (2013)

Profile of glycopyrronium for once-daily treatment of moderate-to-severe COPD
por: Buhl, Roland, et al.
Publicado: (2012)

Efficacy and Safety of Once-Daily Inhaled Umeclidinium in Asian Patients with COPD: Results from a Randomized, Placebo-Controlled Study
por: Zhong, Nanshan, et al.
Publicado: (2020)

Estimation of the Clinical and Economic Impact of an Improvement in Adherence Based on the Use of Once-Daily Single-Inhaler Triple Therapy in Patients with COPD
por: Miravitlles, Marc, et al.
Publicado: (2020)

Once-daily single-inhaler versus twice-daily multiple-inhaler triple therapy in patients with COPD: lung function and health status results from two replicate randomized controlled trials
por: Ferguson, Gary T., et al.
Publicado: (2020)

Geographic variations of the prevalence and distribution of COPD phenotypes in Spain: “the ESPIRAL-ES study”
por: Alcázar-Navarrete, Bernardino, et al.
Publicado: (2018)

Quantifying the Economic Impact of Delayed Multiple-Inhaler Triple Therapy Initiation in Patients with COPD: A Retrospective Cohort Study of Linked Electronic Medical Record and Hospital Administrative Data in England
por: Sansbury, Leah B, et al.
Publicado: (2021)

Efficacy and safety of once-daily inhaled umeclidinium/vilanterol in Asian patients with COPD: results from a randomized, placebo-controlled study
por: Zheng, Jinping, et al.
Publicado: (2015)

Testing for alpha-1 antitrypsin in COPD in outpatient respiratory clinics in Spain: A multilevel, cross-sectional analysis of the EPOCONSUL study
por: Calle Rubio, Myriam, et al.
Publicado: (2018)

Profile of glycopyrronium for once-daily treatment of moderate-to-severe COPD [Corrigendum]
Publicado: (2014)

Role of once-daily glycopyrronium bromide (NVA237) in the management of COPD
por: D’Urzo, Anthony
Publicado: (2013)

Indacaterol, A Novel Once Daily Inhaled β2-Adrenoreceptor Agonist
por: Roig, Jorge, et al.
Publicado: (2009)

Randomised trial of once-daily vilanterol in children with asthma on inhaled corticosteroid therapy
por: Oliver, Amanda J., et al.
Publicado: (2016)

Correction: Testing for alpha-1 antitrypsin in COPD in outpatient respiratory clinics in Spain: A multilevel, cross-sectional analysis of the EPOCONSUL study
por: Calle Rubio, Myriam, et al.
Publicado: (2019)

Validation of clinical control in COPD as a new tool for optimizing treatment
por: Soler-Cataluña, Juan José, et al.
Publicado: (2018)

Lack of Clinical Control in COPD Patients Depending on the Target and the Therapeutic Option
por: Soler-Cataluña, Juan José, et al.
Publicado: (2023)

The dose of inhaled corticosteroids in patients with COPD: when less is better
por: Izquierdo, José Luis, et al.
Publicado: (2018)

Clinical Control Criteria to Determine Disease Control in Patients with Severe COPD: The CLAVE Study
por: Soler-Cataluña, Juan José, et al.
Publicado: (2021)

Revefenacin: A Once-Daily, Long-Acting Bronchodilator For Nebulized Treatment Of COPD
por: Donohue, James F, et al.
Publicado: (2019)

DElaying Disease Progression In COPD with Early Initiation of Dual Bronchodilator or Triple Inhaled PharmacoTherapy (DEPICT): A Predictive Modelling Approach
por: Singh, Dave, et al.
Publicado: (2023)

Long-term cost and utility consequences of short-term clinically important deterioration in patients with chronic obstructive pulmonary disease: results from the TORCH study
por: Paly, Victoria Federico, et al.
Publicado: (2019)

Cannot write session to /tmp/vufind_sessions/sess_obuin7bi3q2qigladipda6d3rb